CN108473571B - 结合人Fc受体的融合蛋白 - Google Patents

结合人Fc受体的融合蛋白 Download PDF

Info

Publication number
CN108473571B
CN108473571B CN201680039811.XA CN201680039811A CN108473571B CN 108473571 B CN108473571 B CN 108473571B CN 201680039811 A CN201680039811 A CN 201680039811A CN 108473571 B CN108473571 B CN 108473571B
Authority
CN
China
Prior art keywords
ser
val
pro
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680039811.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108473571A (zh
Inventor
R·A·格里芬
D·P·哈姆费雷斯
S·J·彼特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CN108473571A publication Critical patent/CN108473571A/zh
Application granted granted Critical
Publication of CN108473571B publication Critical patent/CN108473571B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680039811.XA 2015-07-06 2016-07-06 结合人Fc受体的融合蛋白 Expired - Fee Related CN108473571B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1511787.2 2015-07-06
GBGB1511787.2A GB201511787D0 (en) 2015-07-06 2015-07-06 Proteins
PCT/EP2016/065914 WO2017005767A1 (en) 2015-07-06 2016-07-06 Fusion proteins which bind to human fc receptors

Publications (2)

Publication Number Publication Date
CN108473571A CN108473571A (zh) 2018-08-31
CN108473571B true CN108473571B (zh) 2022-04-15

Family

ID=54013529

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680039811.XA Expired - Fee Related CN108473571B (zh) 2015-07-06 2016-07-06 结合人Fc受体的融合蛋白

Country Status (10)

Country Link
US (1) US20180194856A1 (enExample)
EP (1) EP3319991A1 (enExample)
JP (1) JP7097293B2 (enExample)
CN (1) CN108473571B (enExample)
AU (1) AU2016290523B2 (enExample)
BR (1) BR112017028331A2 (enExample)
CA (1) CA2991363A1 (enExample)
EA (1) EA201890225A1 (enExample)
GB (1) GB201511787D0 (enExample)
WO (1) WO2017005767A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016139006A (ru) 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
SG11201900427PA (en) 2016-07-22 2019-02-27 Gliknik Inc Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
JP7351835B2 (ja) * 2017-12-14 2023-09-27 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
EP3765492A1 (en) * 2018-03-16 2021-01-20 Liverpool School of Tropical Medicine Chimeric fc receptor binding proteins and uses thereof
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业（上海）股份有限公司 一种cdc平台抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073692A1 (en) * 2009-12-18 2011-06-23 The University Of Nottingham Proteins, nucleic acid molecules and compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
AU2012392760C1 (en) * 2012-10-17 2021-08-12 CSL Behring Lengnau AG Immunomodulatory proteins
EP3114137A1 (en) * 2014-03-05 2017-01-11 UCB Biopharma SPRL Multimeric fc proteins
RU2016139006A (ru) * 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
WO2016139365A1 (en) * 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073692A1 (en) * 2009-12-18 2011-06-23 The University Of Nottingham Proteins, nucleic acid molecules and compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Addition of a μ-Tailpiece to IgG Results in Polymeric Antibodies with Enhanced Effector Functions Including Complement-Mediated Cytolysis by lgG4;Richard I. F.等;《The Journal of Immunology》;19951231;第154卷(第5期);摘要，第2228页右栏图1 *
Developmental Regulation of IgM Secretion: The Role of the Carboxy-Terminal Cysteine;Roberto Sitia等;《Cell》;19900309;第60卷;摘要，第783-784页，第787页右栏第1段 *
Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody;Christina Brunke等;《mAbs》;20131231;第5卷(第6期);摘要 *
Roberto Sitia等.Developmental Regulation of IgM Secretion: The Role of the Carboxy-Terminal Cysteine.《Cell》.1990,第60卷第781-790页. *

Also Published As

Publication number Publication date
CA2991363A1 (en) 2017-01-12
WO2017005767A1 (en) 2017-01-12
GB201511787D0 (en) 2015-08-19
CN108473571A (zh) 2018-08-31
EP3319991A1 (en) 2018-05-16
BR112017028331A2 (pt) 2018-09-11
US20180194856A1 (en) 2018-07-12
AU2016290523B2 (en) 2022-08-25
AU2016290523A1 (en) 2018-01-18
EA201890225A1 (ru) 2018-06-29
JP7097293B2 (ja) 2022-07-07
JP2018519834A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
KR102874694B1 (ko) 산성 pH에서 VISTA에 결합하는 항체
CN106715471B (zh) 抗cd127的抗体
CA2719924C (en) Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CN102167740B (zh) 一种全人源抗vegf单克隆抗体、其制备方法及用途
KR20110083730A (ko) Ｃｄ37 면역치료제 병용 요법 및 이의 용도
CN105143259B (zh) Pan-ELR+ CXC 趋化因子抗体
TW202504926A (zh) 抗ｃｄ３８抗體之皮下給藥
CN109451728A (zh) 抗pacap抗体及其用途
RS66491B1 (sr) Anti-fcrn antitela
CN111954680A (zh) IL2Rβ/共同γ链抗体
AU2016290523B2 (en) Fusion proteins which bind to human Fc receptors
JP7695200B2 (ja) Ｇｉｔｒに特異的に結合するモノクローナル抗体
CN106519036B (zh) 抗cd47和egfr的双功能蛋白及其制备方法与应用
KR102916165B1 (ko) 중증근무력증의 치료 방법
ES2692173T3 (es) Anticuerpos monoclonales anti-RHD
CN112638932A (zh) 人源性抗(聚-ga)二肽重复序列(dpr)抗体
KR20220065816A (ko) 산성 pH에서 VISTA에 결합하는 항체
CN114053403A (zh) 融合蛋白在制备疫苗佐剂或预防和治疗病毒感染的药物中的用途
CN110317276A (zh) 一种重组抗体样t细胞抗原受体、t细胞抗原受体偶联药物及应用
CN102167743B (zh) 一种全人源抗egfr单克隆抗体、其制备方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Brussels

Applicant after: UCB biopharmaceutical Co.,Ltd.

Address before: Brussels

Applicant before: UCB BIOPHARMA SPRL

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220415

CF01 Termination of patent right due to non-payment of annual fee